Last updated: October 15, 2026
Dorzolamide hydrochloride is a mature, off-patent ophthalmic carbonic anhydrase inhibitor used to reduce elevated intraocular pressure in open-angle glaucoma and ocular hypertension. The market is genericized, price-sensitive, and fragmented across manufacturers. Commercial value has shifted from the original Trusopt brand to generic dorzolamide, fixed-dose dorzolamide-timolol, and broader glaucoma combinations.
Standalone global revenue is not publicly reported with sufficient consistency to support a precise market-size estimate. The financial profile is clear, however: dorzolamide hydrochloride is a low-growth, low-margin generic opportunity whose value depends on manufacturing cost, supply reliability, institutional contracts, and combination-product positioning.
What is dorzolamide hydrochloride and how is it used?
Dorzolamide hydrochloride is a topical ophthalmic carbonic anhydrase inhibitor. The standard product is a 2% ophthalmic solution administered three times daily as monotherapy or twice daily when used with an ophthalmic beta blocker.[1]
| Attribute |
Detail |
| Active ingredient |
Dorzolamide hydrochloride |
| Drug class |
Topical carbonic anhydrase inhibitor |
| Main indications |
Elevated intraocular pressure, ocular hypertension, open-angle glaucoma |
| Common strength |
2% ophthalmic solution |
| Original brand |
Trusopt |
| Fixed-dose combination |
Dorzolamide hydrochloride 2% and timolol maleate 0.5% |
| Combination brand |
Cosopt |
| Regulatory category |
Small-molecule prescription ophthalmic drug |
| Biosimilar pathway |
Not applicable |
| Primary substitutes |
Prostaglandin analogs, beta blockers, alpha-2 agonists, rho kinase inhibitors, combination products |
Dorzolamide lowers intraocular pressure by reducing aqueous humor production. Its main commercial use is as an adjunct when a prostaglandin analog or beta blocker does not provide adequate pressure control, or when those therapies are unsuitable.[1]
When did dorzolamide hydrochloride lose exclusivity?
The original U.S. exclusivity period has ended. Trusopt was approved by the FDA in 1994, and Cosopt was approved in 1998.[2][3] The relevant composition, formulation, and product-specific protection associated with the original products has expired or no longer prevents generic competition.
Dorzolamide is therefore a mature generic product rather than a protected branded asset.
| Milestone |
Approximate timing |
Commercial effect |
| Trusopt U.S. approval |
1994 |
Established dorzolamide as a glaucoma therapy |
| Cosopt U.S. approval |
1998 |
Created a higher-value fixed-dose combination |
| Generic competition |
Following expiry of original protection |
Reduced branded pricing and market share |
| Current status |
Mature generic market |
Value determined by cost, supply, and contracting |
The exact patent landscape depends on jurisdiction, dosage form, and whether the product is evaluated as dorzolamide alone or as a fixed-dose combination. The original product estate does not create a meaningful barrier to ordinary generic entry in the United States.
What patents protect dorzolamide hydrochloride?
No active U.S. patent estate is generally understood to provide durable market exclusivity for ordinary dorzolamide hydrochloride 2% ophthalmic solution. The original protection covered the active compound and product technology developed for Trusopt. Those rights are no longer a material obstacle to generic approval.
Patent issues can still arise in three areas:
- Formulation patents: These may cover preservatives, viscosity modifiers, pH control, container systems, or other ophthalmic formulation characteristics.
- Fixed-dose combinations: Dorzolamide-timolol products may have separate product or formulation claims from dorzolamide monotherapy.
- Manufacturing patents: Patents can cover crystalline forms, impurity-control methods, synthesis intermediates, or process conditions.
These rights generally have less commercial impact than the expired core product patents unless they are listed in the FDA Orange Book or asserted against a specific abbreviated new drug application.
What is the Orange Book status of dorzolamide?
The FDA Orange Book remains the controlling source for current U.S. patent listings and regulatory exclusivity. Mature dorzolamide products do not generally carry a current exclusivity period comparable to a new chemical entity, pediatric exclusivity, or an unexpired core product patent.[4]
The commercial implications are:
- Generic applicants can use the abbreviated new drug application pathway.
- Applicants may file Paragraph IV certifications against any listed unexpired patent.
- A generic applicant does not need to repeat full clinical efficacy trials.
- A formulation or combination patent can still affect a particular product even when the active ingredient is off patent.
An Orange Book listing is product-specific. A patent listed against Cosopt or a particular ophthalmic formulation should not automatically be treated as a barrier to all dorzolamide products.
Are there Paragraph IV challenges involving dorzolamide?
Paragraph IV litigation is most relevant to any remaining listed patent covering a specific dorzolamide product, combination, or formulation. The core dorzolamide opportunity is already genericized, so the strategic importance of new Paragraph IV activity is limited compared with recently launched branded drugs.
Generic companies have historically entered mature ophthalmic markets through:
- ANDAs for dorzolamide ophthalmic solution;
- ANDAs for dorzolamide-timolol ophthalmic solution;
- alternative preservative or container configurations;
- authorized or private-label generic supply agreements.
A Paragraph IV filing can trigger a 30-month stay under the Hatch-Waxman framework if the relevant conditions are met, but that mechanism is unlikely to preserve meaningful commercial exclusivity for the original dorzolamide brand at this stage.[5]
What formulations are protected by dorzolamide patents?
The principal commercial formulations are dorzolamide 2% ophthalmic solution and dorzolamide-timolol fixed-dose ophthalmic solution.
Dorzolamide ophthalmic solution
The product is an aqueous multidose ophthalmic solution. Formulation considerations include:
- chemical stability;
- ocular tolerability;
- pH;
- preservative concentration;
- container compatibility;
- drop-size consistency;
- microbial protection during multidose use.
Generic manufacturers can compete without duplicating every excipient or manufacturing parameter used by the branded product, provided the final product meets FDA requirements for pharmaceutical equivalence and bioequivalence under the applicable ophthalmic standards.
Dorzolamide-timolol combination
Cosopt combines two established mechanisms: carbonic anhydrase inhibition and beta-adrenergic blockade. The combination improves convenience by reducing the number of bottles and administration steps. Its commercial value is higher than dorzolamide monotherapy in some channels because adherence and prescription substitution can support fixed-dose products.
Preservative-free versions are commercially important in patients with ocular-surface disease or chronic exposure to benzalkonium chloride. They can command better pricing than standard preserved generic solutions, but they also require more complex packaging and manufacturing controls.
How does dorzolamide compare with competing glaucoma drugs?
Dorzolamide competes in a large, mature glaucoma market dominated by prostaglandin analogs and generic combinations.
| Product class |
Examples |
Main advantage |
Commercial position |
| Prostaglandin analogs |
Latanoprost, travoprost, bimatoprost |
Strong once-daily efficacy |
Usually first-line therapy |
| Beta blockers |
Timolol |
Low cost and long clinical history |
Common generic adjunct |
| Carbonic anhydrase inhibitors |
Dorzolamide, brinzolamide |
Useful adjunctive pressure reduction |
Mature generic segment |
| Alpha-2 agonists |
Brimonidine |
Additional mechanism |
Generic, but tolerability limits use |
| Fixed combinations |
Dorzolamide-timolol, brimonidine-timolol |
Fewer administration steps |
Higher value than single agents |
| Rho kinase inhibitors |
Netarsudil |
Newer mechanism |
Branded or limited-competition segment |
Dorzolamide has weaker commercial differentiation than once-daily prostaglandin analogs because it generally requires more frequent administration. It remains relevant when clinicians need additional pressure reduction or want to avoid systemic beta-blocker exposure.
What is the financial trajectory for dorzolamide hydrochloride?
The financial trajectory has four stages:
- Branded growth: Trusopt generated value as an innovative glaucoma product after its 1994 approval.
- Combination expansion: Cosopt extended the commercial franchise by combining dorzolamide with timolol.
- Generic erosion: Generic entry reduced price and branded volume.
- Mature-market stabilization: Revenue became dependent on low-cost supply, contracting, and combination products.
Merck does not generally report Trusopt or Cosopt as standalone revenue lines in its public financial disclosures. The company reports broader business segments, which prevents a reliable current revenue estimate for the individual products.[6]
| Financial driver |
Direction |
Effect on dorzolamide economics |
| Generic competition |
Negative |
Compresses price and gross margin |
| Ophthalmology demand |
Positive |
Supports durable unit demand |
| Aging population |
Positive |
Expands treated glaucoma population |
| Prostaglandin-first prescribing |
Negative |
Limits monotherapy growth |
| Fixed-dose combinations |
Positive |
Improves value per prescription |
| Preservative-free formats |
Positive |
Supports premium pricing |
| Pharmacy benefit contracting |
Negative |
Reduces net price |
| Manufacturing concentration |
Mixed |
Can support scale but increases shortage risk |
| Hospital and government tenders |
Negative |
Intensifies price competition |
The product is unlikely to deliver material revenue growth through volume expansion alone. A manufacturer seeking attractive economics would need to target supply-constrained channels, preservative-free formats, private-label contracts, or combination products.
Which companies compete in the dorzolamide market?
Competition includes branded suppliers, generic ophthalmic specialists, diversified generic manufacturers, and contract manufacturers. The exact supplier roster changes by country and by pharmacy channel.
Typical competitors include:
- large generic manufacturers with ophthalmic production;
- specialty ophthalmology companies;
- regional pharmaceutical companies;
- authorized generic suppliers;
- contract development and manufacturing organizations.
In the United States, competition is shaped by FDA-approved ANDAs, wholesaler concentration, group-purchasing contracts, and the ability to maintain sterile ophthalmic production. In Europe, market access is more fragmented because reimbursement, tendering, and reference pricing vary by country.
The relevant competitive advantage is operational rather than patent-based. Manufacturing reliability, inspection history, batch release capacity, and preservative-free packaging can determine market share more than clinical differentiation.
What generic entry risks exist for dorzolamide hydrochloride?
Generic entry risk is already realized for the core product. Future risks concern margin erosion and substitution rather than a sudden loss of exclusivity.
Key risks include:
- additional ANDA approvals;
- aggressive pharmacy-benefit substitution;
- wholesaler inventory reductions;
- tender-based price declines;
- product recalls or manufacturing interruptions;
- supply replacement by dorzolamide-timolol combinations;
- clinician migration to once-daily prostaglandin analogs;
- substitution by brinzolamide or newer agents.
Dorzolamide products also carry manufacturing complexity. Ophthalmic solutions require sterile processing, validated filling, container-closure integrity, and tight control of visible and subvisible particles. These requirements create an operational barrier, but not a durable patent barrier.
What FDA regulatory status applies to dorzolamide?
Dorzolamide hydrochloride ophthalmic products are approved prescription drugs regulated through the FDA’s drug approval framework. Generic versions are generally approved through ANDAs rather than full NDAs when they demonstrate pharmaceutical equivalence and bioequivalence to the reference product.[4][7]
FDA review focuses on:
- active ingredient identity and strength;
- dosage form and route;
- sterility;
- impurities and degradation products;
- container closure;
- preservative performance where applicable;
- labeling;
- manufacturing compliance.
Dorzolamide is a small molecule. Biosimilar competition is not relevant. The competitive pathway is generic substitution, not the biologics license application or biosimilar pathway.
What patent litigation and settlements affect dorzolamide?
The principal litigation risk was associated with the original branded products and generic entry. The commercial importance of new litigation is now limited unless a manufacturer introduces a differentiated formulation, preservative-free product, delivery device, or combination product with a live patent estate.
There is no broad, current litigation framework comparable to the patent disputes surrounding recently launched specialty drugs. Settlement agreements involving the original Trusopt franchise would generally have limited present-day value because the core product has already moved into a generic market.
For diligence purposes, litigation review should focus on:
- current Orange Book entries;
- ANDA litigation involving a specific applicant;
- product liability and manufacturing cases;
- FDA warning letters or recalls;
- formulation patents attached to preservative-free products.
How strong is the dorzolamide hydrochloride patent estate?
The patent estate is weak for the basic active ingredient and standard ophthalmic solution. It is potentially stronger for narrow formulation, packaging, combination, and manufacturing claims, but those rights are unlikely to support broad market exclusivity.
| Estate component |
Current strength |
| Core active ingredient |
Low |
| Standard 2% ophthalmic solution |
Low |
| Dorzolamide-timolol combination |
Low to moderate, depending on jurisdiction and claim scope |
| Preservative-free formulation |
Moderate if supported by valid, unexpired claims |
| Delivery device |
Variable |
| Manufacturing process |
Moderate for enforcement against identical processes |
| Regulatory exclusivity |
None expected for mature products |
Geographic coverage is also uneven. A patent that has expired in the United States may remain relevant in a country where examination, patent term adjustment, supplementary protection, or national filing timelines differ. Commercial diligence should therefore evaluate the United States, European Union, Japan, China, India, Brazil, and other priority markets separately.
What licensing deals affect dorzolamide?
No major current licensing transaction is central to the standard generic dorzolamide market. The original franchise was developed and commercialized by Merck, while later market participation has relied mainly on generic approvals, distribution contracts, and private-label supply arrangements.
Potential deal value is more likely to arise from:
- acquisition of an approved ANDA;
- transfer of an ophthalmic manufacturing site;
- private-label supply;
- regional commercialization rights;
- preservative-free or device-based formulations.
A licensing transaction for ordinary dorzolamide 2% solution would likely be evaluated as a manufacturing and distribution deal rather than an innovation-led royalty transaction.
Key Takeaways
- Dorzolamide hydrochloride is a mature, off-patent glaucoma medicine.
- Trusopt and Cosopt established the original branded market, but generic entry has removed broad product exclusivity.
- The core opportunity is low growth and price sensitive.
- Fixed-dose dorzolamide-timolol and preservative-free products offer better commercial positioning than standard monotherapy.
- No biosimilar risk exists because dorzolamide is a small molecule.
- Patent value is concentrated in narrow formulation, packaging, combination, and manufacturing claims.
- Public company filings do not provide reliable standalone current revenue for dorzolamide.
- The principal investment variables are sterile manufacturing capacity, supply continuity, contracting power, and product differentiation.
FAQs About Dorzolamide Hydrochloride Market and Patents
Is dorzolamide hydrochloride still a profitable drug?
It can be profitable at scale, but ordinary generic dorzolamide is unlikely to produce branded-drug margins. Profitability depends on manufacturing efficiency, volume contracts, shortage conditions, and differentiated packaging.
Is dorzolamide hydrochloride a generic drug?
Yes. Dorzolamide hydrochloride ophthalmic solution is widely available as a generic prescription drug in major markets.
Does dorzolamide hydrochloride have biosimilar competition?
No. Biosimilars apply to biologic medicines. Dorzolamide is a chemically synthesized small molecule and competes through generic drug approvals.
Is Cosopt more commercially attractive than dorzolamide alone?
Usually. The fixed-dose combination can support better prescription retention and convenience, although it remains exposed to generic pricing and competition from other glaucoma combinations.
Can a new company obtain exclusivity for a dorzolamide product?
Potentially, but only through a differentiated formulation, delivery system, manufacturing innovation, or other patentable improvement. A standard dorzolamide ophthalmic solution would not ordinarily create meaningful new market exclusivity.
References
- U.S. Food and Drug Administration. (2017). Trusopt (dorzolamide hydrochloride ophthalmic solution) prescribing information. FDA.
- U.S. Food and Drug Administration. (1994). NDA 20-408: Trusopt approval history. Drugs@FDA.
- U.S. Food and Drug Administration. (1998). NDA 20-785: Cosopt approval history. Drugs@FDA.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA, Orange Book.
- U.S. Code, 21 U.S.C. § 355(j). Abbreviated applications and patent certifications.
- Merck & Co., Inc. (1995–2024). Annual reports and Form 10-K filings.
- U.S. Food and Drug Administration. (2024). ANDA submissions: Product-specific guidance and generic drug approval standards. FDA.
